A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

计划入组 16 人 · 首次发布于 2017 年 7 月 2 日

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

计划入组 20 人 · 首次发布于 2005 年 5 月 11 日

GC-PRO Intervention

计划入组 994 人 · 首次发布于 2024 年 11 月 4 日

anti-CD3/undisclosed target 3 bispecific T-cell engager XPAT/Pro-XTEN (Amunix)

anti-CD3/undisclosed target bispecific T-cell engager (XPAT/Pro-XTEN, solid tumors)

Exenatide-XTEN

PRO-IMPLANT Foundation

Germany

Alpha Pro Tech

Pro Top & Mediking Company Limited

Vir Biotechnology to Present Phase 1 Data on PRO-XTEN Masked T-Cell Engagers

Vir Biotechnology Licenses Masked T-Cell Engagers from Sanofi to Expand Oncology Pipeline

Vir Biotechnology's Stock Surges on Promising T-Cell Engager Data in Solid Tumors and Prostate Cancer